www.fdanews.com/articles/85271-adipogenix-achieves-third-milestone-in-collaboration-with-johnson-johnson
ADIPOGENIX ACHIEVES THIRD MILESTONE IN COLLABORATION WITH JOHNSON & JOHNSON
March 14, 2006
AdipoGenix Inc., a biopharmaceutical
company developing small molecule therapies for obesity, type 2 diabetes and associated
morbidities, today announced the achievement of its third milestone in the Company's
drug discovery collaboration with Johnson & Johnson (J&J). In November
2002, AdipoGenix and J&J entered a drug discovery collaboration in which AdipoGenix
has utilized its proprietary human fat cell-based technologies for discovering
compounds that reduce the fat content of human fat cells from J&J's compound
collection.
PR
Newswire